Innovations in self-administration technologies, such as auto-injectors, prefilled syringes and wearable injectors have significantly reshaped the landscape of biologic drug delivery. These technologies help ensure accurate dosing and better patient outcomes while also increasing convenience and adherence for those managing chronic conditions. As biosimilar adoption continues to grow, companies investing in advanced delivery methods are well-positioned to take advantage of expanding market opportunities.
Advanced formulation technologies for biosimilars represent a critical area of growth. These formulations enhance stability, bioavailability and efficacy, creating opportunities for longer shelf life, less frequent dosing and improved therapeutic outcomes. Investing in modern formulation and delivery methods can give companies a competitive edge, especially in markets where convenience and patient adherence strongly influence prescribing decisions.
The integration of digital technologies into drug delivery devices, including connected injectors and smart packaging, presents another promising opportunity. These devices enable real-time monitoring, dose tracking and adherence support, allowing healthcare professionals to manage patient treatment plans more effectively. Using digital tools not only improves patient care but also opens new revenue opportunities and helps drug developers and healthcare providers stand out in a competitive market.
There are also significant opportunities in developing high-performance biocompatible materials and excipients that support biosimilar formulations. These components play a vital role in preserving the stability and effectiveness of biologic drugs. They continue to drive progress in drug delivery systems and help address long-standing barriers to broader biosimilar adoption.
The Drug Delivery Summit 2026 is an essential event for pharmaceutical stakeholders, including biosimilar developers, healthcare providers, researchers, regulators, policymakers, investors and technology innovators. Attendees will engage with innovative solutions, strategic perspectives and collaborative opportunities that support progress in the evolving biosimilars landscape. The program will focus on how to harness emerging drug delivery trends and address key challenges in delivering biologic therapies efficiently and sustainably.
